| Demographics, n (%) |
| Age, mean (range) | 41.6 (23-69) y | 42.7 (19-84) y |
| Sex | M 36 (71)/F 15 (29) | M 40 (78)/F 11 (22) |
| HLA-B27 status | Positive 43 (84.3) | Positive 45 (88.2) |
| Negative 8 (15.7) | Negative 6 (11.8) |
| Disease duration | ≤10 y 39 (76.5) | ≤10 y 34 (66.7) |
| >10 y 12 (23.5) | >10 y 17 (33.3) |
| Baseline BASDAI, mean (range) | 6.62 (2.9-9.5) | 6.77 (4.2-9.7) |
| Efficacy Endpoint, n (%) |
| ASAS20 | 19 (37.3) | 14 (27.5) |
| ASAS20 (baseline CRP <3× ULN) | 6 (23.1) | 6 (27.3) |
| ASAS20 (baseline CRP ≥3× ULN) | 13 (52.0) | (27.6) |
| ASAS40 | 6 (11.8) | 10 (19.6) |
| BASDAI (<4) | 1 (2.0) | 0 (0.0) |
| BASDAI50 | 3 (5.9) | 5 (9.8) |
| ASDAS-CRP (mean change) | –1.40 | –0.44 |